An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade

Li,Long; Li,Xiaojun; Han,Xiaobing; Yang,Ting; Fu,Jing; Zhang,Yunfeng; Gou,Wenli

doi:10.3892/or.2014.3284

An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade

Authors:
- Long Li
- Xiaojun Li
- Xiaobing Han
- Ting Yang
- Jing Fu
- Yunfeng Zhang
- Wenli Gou
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Second Thoracosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: June 23, 2014 https://doi.org/10.3892/or.2014.3284
Pages: 943-950

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Approximately 60% of ovarian cancers are positive for the estrogen receptor (ER); however, ER-targeted treatment is disappointing due to drug resistance as compared with breast cancer. In estrogen-sensitive cancers, estrogen activates Src to phosphorylate p27 promoting its degradation and increasing cell cycle progression. Since Src is frequently activated in ovarian cancers, we investigated whether combined Src and ER blockade by saracatinib and fulvestrant would circumvent anti-estrogen resistance. In 20 out of 40 enrolled patients with immunohistochemically ER-positive ovarian cancer, phosphorylated Src (p-Src) at the site of 416 tyrosine was expressed with a propensity for metastasis and a poorer disease-free survival (DFS) at 3 years following ER antagonist treatment. The effects of ER and Src blockade on cell cycle were assayed in estrogen receptor α (ERα)-positive ovarian cancer. We observed that Src activity was fairly greater in anti-estrogen-resistant ovarian cancer cells than that in the anti-estrogen-sensitive cell line. Estrogen activated Src via ER-Src binding and ER translocation from cytoplasm to nucleus. Mitogenesis was mediated via ERα, not ERβ. Combined saracatinib and fulvestrant increased p27 and inhibited cell cycle progression. Furthermore, dual therapy induced autophagy and inhibited ovarian cancer xenograft growth more effectively than monotherapy. Saracatinib facilitated the therapeutic effects of fulvestrant by antagonizing the estrogen-mediated Src activation. These are supportive of further preclinical assessment of combined fulvestrant and saracatinib in patients with ovarian cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
3	Simpkins F, Hevia-Paez P, Sun J, et al: Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res. 18:5911–5923. 2012. View Article : Google Scholar : PubMed/NCBI
4	Argenta PA, Um I, Kay C, et al: Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol Oncol. 131:368–373. 2013. View Article : Google Scholar : PubMed/NCBI
5	Badia E, Docquier A, Busson M, et al: Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. J Steroid Biochem Mol Biol. 132:176–185. 2012. View Article : Google Scholar : PubMed/NCBI
6	Bossard C, Busson M, Vindrieux D, et al: Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One. 7:e447872012. View Article : Google Scholar : PubMed/NCBI
7	Halon A, Materna V, Drag-Zalesinska M, et al: Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 17:511–518. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kothari R, Argenta P, Fowler J, Carter J and Shimp W: Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature. Arch Oncol. 18:32–35. 2010. View Article : Google Scholar : PubMed/NCBI
9	Smyth JF, Gourley C, Walker G, et al: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 13:3617–3622. 2007. View Article : Google Scholar : PubMed/NCBI
10	Park MA, Hwang KA, Lee HR, Yi BR, Jeung EB and Choi KC: Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models. Toxicology. 305:41–48. 2013. View Article : Google Scholar
11	Wang L, Wang G, Yang D, et al: Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. Mol Med Rep. 8:1279–1285. 2013.PubMed/NCBI
12	Jiang D, Wang X, Liu X and Li F: Gene delivery of cyclin-dependent kinase inhibitors p21^Waf1 and p27^Kip1 suppresses proliferation of MCF-7 breast cancer cells in vitro. Breast Cancer. 2013.[Epub ahead of print].
13	Psyrri A, Bamias A, Yu Z, et al: Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 11:8384–8390. 2005. View Article : Google Scholar
14	Hurteau JA, Allison BM, Brutkiewicz SA, et al: Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27^Kip1 in epithelial ovarian cancer. Gynecol Oncol. 83:292–298. 2001. View Article : Google Scholar : PubMed/NCBI
15	Xing D and Orsulic S: A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA. 102:6936–6941. 2005. View Article : Google Scholar : PubMed/NCBI
16	Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
17	Huang YW, Chen C, Xu MM, Li JD, Xiao J and Zhu XF: Expression of c-Src and phospho-Src in epithelial ovarian carcinoma. Mol Cell Biochem. 376:73–79. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kim HS, Han HD, Armaiz-Pena GN, et al: Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 17:1713–1721. 2011.
19	Matsuo K, Nishimura M, Bottsford-Miller JN, et al: Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 17:5367–5378. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhao Y, Li X, Sun X, Zhang Y and Ren H: EMT phenotype is induced by increased Src kinase activity via Src-mediated caspase-8 phosphorylation. Cell Physiol Biochem. 29:341–352. 2012. View Article : Google Scholar : PubMed/NCBI
21	Castoria G, Giovannelli P, Lombardi M, et al: Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene. 31:4868–4877. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chu I, Sun J, Arnaout A, et al: p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 128:281–294. 2007. View Article : Google Scholar : PubMed/NCBI
23	Serkies K, Sinacki M and Jassem J: The role of hormonal factors and endocrine therapy in ovarian cancer. Contemp Oncol. 17:14–19. 2013.PubMed/NCBI
24	Brenton JD and Stingl J: Stem cells: anatomy of an ovarian cancer. Nature. 495:183–184. 2013. View Article : Google Scholar : PubMed/NCBI
25	Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 25:486–492. 2007.PubMed/NCBI
26	Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 12:1101–1108. 2011.PubMed/NCBI
27	Jung J, Kim HY, Kim M, Sohn K, Kim M and Lee K: Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src. Oncogene. 30:2264–2274. 2011. View Article : Google Scholar : PubMed/NCBI
28	Hui AY, Meens JA, Schick C, et al: Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells. J Cell Biochem. 107:1168–1181. 2009. View Article : Google Scholar : PubMed/NCBI
29	Nautiyal J, Yu Y, Aboukameel A, et al: ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther. 9:1503–1514. 2010. View Article : Google Scholar : PubMed/NCBI
30	Moulder S, Yan K, Huang F, et al: Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 9:1120–1127. 2010. View Article : Google Scholar : PubMed/NCBI
31	Gucalp A, Sparano JA, Caravelli J, et al: Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer. 11:306–311. 2011. View Article : Google Scholar : PubMed/NCBI
32	Arcaroli JJ, Touban BM, Tan AC, et al: Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res. 16:4165–4177. 2010. View Article : Google Scholar : PubMed/NCBI
33	Boya P, Reggiori F and Codogno P: Emerging regulation and functions of autophagy. Nat Cell Biol. 15:713–720. 2013. View Article : Google Scholar : PubMed/NCBI
34	Choi AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med. 368:651–662. 2013. View Article : Google Scholar : PubMed/NCBI
35	Fimia GM, Corazzari M, Antonioli M and Piacentini M: Ambra1 at the crossroad between autophagy and cell death. Oncogene. 32:3311–3318. 2013. View Article : Google Scholar : PubMed/NCBI